LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on CGON stock, giving a Buy rating on September 5.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky’s rating is based on the promising clinical data presented by CG Oncology, Inc. in their recent Phase 3 BOND-003 study. The study showcased an improved 24-month complete response rate for their treatment, cretostimogene, in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer. This improvement in efficacy, from a previous rate of 33.7% to 41.8%, sets a high benchmark for competitors in the field.
Moreover, cretostimogene’s performance is favorable when compared to other late-stage competitors like J&J’s TAR-200, particularly in terms of long-term efficacy and safety. The inclusion of patients with prior treatments in CG Oncology’s study further highlights the robustness of their data, as no significant difference in response was observed. Additionally, the completion of enrollment in the Phase 3 PIVOT-006 study ahead of schedule underscores the enthusiasm and potential market opportunity for cretostimogene in treating intermediate-risk non-muscle invasive bladder cancer.
Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Celldex, and Cogent Biosciences. According to TipRanks, Slutsky has an average return of 11.4% and a 39.80% success rate on recommended stocks.
In another report released on September 5, H.C. Wainwright also maintained a Buy rating on the stock with a $75.00 price target.